Daniel H. Palmer, Stefan N. Symeonides, Fiona C. Dempsey, Scott Crichton, Colin Tennant, Chris Wood, Lisa Yule, Sidrah Iftikhar, Jemma Proudfoot-Jones, Magdalena Kielak, Sarah Patricia Blagden. "MDX-124, a first-in-class annexin-A1 targeting antibody, in patients with locally advanced or metastatic solid malignancies: Data supporting RP2D from the dose escalation stage of a first-in-human phase Ib trial.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.e15112